γ-Tocotrienol inhibition of galectin-3 expression, distribution and oligomerization in highly metastatic breast cancer cells

Read full text Summarise with VIRAT
Authors: Jessie J. Grazier, Paul William Sylvester
Cited by: 0
References: 28

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Experimental studies were conducted to compare the relative effects of γ-tocotrienol, a natural isoform within the vitamin E family of compounds, with established galectin-3 inhibitor β-lactose, on galectin-3 levels and distribution in highly metastatic human MDA-MB-231, and mouse + SA and TS/A breast cancer cell lines. In contrast to β-lactose, γ-tocotrienol displays a dual-mode binding profile with the carbohydrate recognition domain and hydrophobic pocket located on galectin-3, as determined using Schrödinger molecular modeling. However, treatment with either γ-tocotrienol or β-lactose induces a significant decrease in galectin-3 expression, oligomerization, and a corresponding decrease in fibronectin fibril and lamellipodial protrusion formation, an indication of treatment-induced reversal in epithelial-mesenchymal transition (EMT). These same treatments also caused a significant decrease in galectin-3 Fluorescence Resonance Energy Transfer (FRET) signaling, as compared to the control group, demonstrating the intricate role of galectin-3 in modulating EMT in metastatic breast cancer cells. Combined treatment of doxorubicin with either γ-tocotrienol or β-lactose results in a large increase in doxorubicin levels in the nuclei of metastatic breast cancer cells, the primary site of action for this chemotherapeutic agent. Taken together these findings demonstrate that γ-tocotrienol-induced reversal of EMT in metastatic breast cancer cells is mediated, at least in part, by a disruption in the galectin-3 expression, distribution and function.

Fields of Study & Subjects

Galectins and Cancer Biology Advanced Glycation End Products research Glycosylation and Glycoproteins Research

Publication details

Journal / source
Scientific Reports
Volume
16
Issue
1
Publication date
26 March 2026
Language
EN